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Letters to the Editor 
Dear Editor 
Effects of N-Acetylcysteine on hyperoxic lung in the 
rat 
It is becoming increasingly recognized that 
exposure to hyperoxia results in pulmonary injury, 
and this is closely related to oxidant-antioxidant 
imbalance in the lung. The main stay of the patho- 
physiology of this condition is the effect of oxygen- 
derived free radicals on the alveolocapillary barrier 
(ACB) (1). Studies have shown that N-acetylcysteine 
(NW, a thiol-containing compound, non- 
enzymatically interacts and detoxifies free radicals 
(2). We have investigated the effectiveness of NAC as 
a cytoprotective agent against hyperoxic pulmonary 
damage in experimental animals. Thirty wistar rats 
(weight 250 f 30 g) were used in these experiments 
and divided into three groups. The first group was 
exposed to 100% oxygen only; the second group 
was pre-treated with NAC 600 mg kg - ’ day ~ ’ for 
5 days, then exposed to 100% oxygen; the third group 
was also pre-treated with NAC as above but exposed 
to ambient air. Animals were killed 24 h later and 
their lungs were removed and examined by light 
microscopy (LM), and transmission electron micros- 
copy (TEM). Focal alveolar haemorrhage/oedema 
was assessed semi-quantitatively, while diffuse 
alveolar congestion and perivascular oedema was 
graded as slight, moderate or severe. 
Thirty-three percent of alveoli showed generalized 
congestion and slight perivascular oedema, in addi- 
tion to enlargement of the alveolar endothelium in 
all animals of the first group. In contrast, the alveoli 
of groups two and three appeared normal, but they 
were infiltrated by a large number of alveolar 
macrophages. 
These results suggest that NAC may act as an 
antioxidant, and reduce oxygen-derived free radicals 
which may increase permeability of ACB (3) and 
therefore reduce the inflammatory response mediated 
by neutrophils (4,5). 
We conclude that NAC can be utilized in the 
prevention of hyperoxic lung damage, as it reduces 
lung injury on ACB cells. 
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Dear Editor 
Home nebulizer service 
We were interested to read about the audit of 
a home nebulizer service provided by respiratory 
care nurse specialists from University Hospital, 
Nottingham. 
As a team of respiratory care nurses (3 full-time 
equivalents), we have been running an efficient 
nebulizer service for the past 5 yr, on much the same 
lines as described in the audit. We have had the 
benefit of a secretary to run the system administra- 
tively and have found that it works extremely well. 
The number of nebulizer compressors required has 
in fact dropped due to more efficient assessment and 
the finding that many patients benefit just as much 
from high dose bronchodilator by large volume 
spacer, as by nebulization. A local maintenance and 
repair service for nebulizers/compressors run by the 
hospital electronics engineering department with the 
co-operation of the manufacturers, has been running 
successfully for the past 2 yr. This is available to all 
patients who have had nebulizers provided by the 
unit, whether under continuing hospital follow-up 
or not. 
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In our protocol, patients are all studied at home 
with a combination of questionnaire response and 
peak flow measurements taken 3 times daily before 
and after the bronchodilator. The regime we use is as 
follows: 
Week One -Normal therapy; 
Week Two -Salbutamol via Spacer; 
Week Three-Salbutamol via Nebulizer; 
Week Four -1pratropium bromide via Spacer; 
Week five -1pratropium bromide via Nebulizer; 
Week Six -1pratropium bromide and Salbutamol 
via Nebulizer. 
This is sometimes varied with reference to the 
patients individual problems. Patient compliance 
with this procedure is good and the home visits give 
the specialist nurses the opportunity to cover many 
other aspects of education and advice about manage- 
ment of their condition; regular contact continues to 
be made after the trial is completed. 
Referrals for such assessments are mainly from the 
Chest Physician. Other consultants in the hospital 
and general practitioners can also refer, but guide- 
lines sent out by the local Chest Consultant make it 
clear that adult patients severe enough to be consid- 
ered for nebulizer therapy should ideally be assessed 
at the hospital, although not necessarily followed-up 
there. 
During the 3 yr audit period of 1990-1993, there 
were a total of 80 nebulizer trials undertaken. Of 
these, 30% had improved using a nebulizer with 
salbutamol, 4% improved with nebulizer with 
salbutamol and ipratropium bromide, 22% improved 
with salbutamol by large volume spacer and 9% 
showed an inconclusive result. The rest felt that 
conventional inhaled dosage was just as good as any 
of the others. 
We would entirely endorse the conclusions of Hall 
et al. (1) that a nebulizer service run totally by a 
respiratory nurse specialist team is not only feasible, 
but desirable. We think that it is also efficient not 
only in ensuring patients are on the right treatment, 
but in also avoiding unnecessary expensive provision 
of nebulizer compressors where they are not useful. 
P. MCINTYRE, L. ATTFIELD, C. HUMPHERSON, 
B. BRADFORD AND R. DENT 
Queen Elizabeth ZZ Hospital 
Welwyn Garden City, U.X 
22 September 1994 
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Dear Editor 
‘Ethnic discounting’ and spirometry 
In their recommendations concerning the measure- 
ment of respiratory function, the BTSlARTP (1) has 
suggested that prediction of FEV, and FVC in indi- 
viduals of African descent may be made more accu- 
rate by discounting 10% from values derived from 
ECCS reference equations (2). With our hetero- 
geneous population in South Africa, we have had 
sufFicient reason to thoroughly evaluate the useful- 
ness of similar recommendations. I believe that 
ethnic discounting contributes nothing useful to the 
accuracy of predictions. 
Any clinician seeking greater accuracy in predict- 
ing an individual’s lung function could, with equal 
authority, enquire after the individual’s birth weight, 
parental socio-economic status, maternal smoking or 
other known determinants of adult spirometry. If 
African ethnic origin is still going to be accounted 
for, then it is useful to know that significant variation 
in observed normal spirometry has been reported 
between African populations (3). Highest values have 
been reported from countries at higher altitudes such 
as Ethiopia and South Africa. Lower values have 
been reported from West Africa and the Caribbean. 
More recent studies have reported higher values, 
possibly as a consequence of secular trends. Although 
values reported from European populations are 
generally higher, there is considerable overlap in 
the values reported from African and European 
populations. 
Interestingly the BTS recommendations represent 
a change from usual previous practice in the U.K. In 
a questionnaire survey conducted in 1990, respon- 
dents at university-affiliated pulmonary function 
laboratories (PFL) were asked how they would pre- 
dict spirometry in clients of African ancestry (4). 
From the U.K., 10 out of 13 PFL replied that they 
would use reference equations based on a study 
carried out more than 20 yr ago in the Caribbean (5). 
From France, 10 out of 11 PFL replied that they 
would use the ECCS prediction equations without 
any correction factors. At that time ethnic discount- 
ing appeared to be an American practice. Eighteen 
out of 35 U.S.A. PFL stated that they would usually 
apply correction factors to their reference equations. 
Sixteen respondents from the U.S.A. would not apply 
a correction factor, and 1 PFL used an ethnically- 
specific prediction equation. 
Usual U.K. practices for predicting spirometry in 
Africans may be in need of an update. Given the 
variety of possible choices on what to recommend, it 
would be interesting to know why the BTS/ARTP 
